Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.

Ipsen

Status: Terminated

Conditions: Pancreatic Neuroendocrine Tumor

Study type: Observational

Funder types: Industry

Identifiers

NCT03947762

IPS-LAN-2018-01 (Other Identifier)

A-ES-52030-383

Details and patient eligibility

About

The purpose of the protocol is to estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment, at 24 months after treatment initiation with lanreotide 120 mg every 28 days.

Enrollment: 54 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects aged ≥ 18
• Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months
• Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation
• Subject with Eastern Cooperative Oncology Group (ECOG) ≤2

Exclusion criteria

• Subject who is participating in an interventional study
• Pregnant or breast-feeding women
• Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours